Skip to main content

Table 1 Baseline clinical and tumor characteristics

From: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization

Baseline characteristics

N (%)/ median (IQR) (N = 166)

Sex (male)

127 (76.5%)

Age (years)

65 (57.75–72)

Etiologies of liver disease

 HBV infection

 HCV infection

 NASH

 Cryptogenic

 Alcohol

 AIH

73 (44.0%)

50 (30.1%)

16 (9.6%)

14 (8.4%)

12 (7.3%)

1 (0.6%)

Cirrhosis 156(94.0%)

 CTP A

  - Score 5

  - Score 6

 CTP B

 -  Score 7

  - Score 8

134 (80.7%)

87 (52.4%)

47 (28.3%)

22 (13.3%)

17 (10.2%)

 5 (3.0%)

MELD score

8.88 (7.69 – 10.43)

Number of HCC

 1

 2–3

  > 3

49 (25.3%)

57 (34.4%)

67 (40.4%)

Location of HCC

 Both lobes

 Right lobe

 Left lobe

76 (45.8%)

75 (45.2%)

15 (9.0%)

Largest tumor diameter (cm)

 

  ≤ 3

  > 3—≤ 7

  > 7—≤ 10

  > 10

16 (9.6%)

77 (46.4%)

42 (25.3%)

31 (18.7%)

  1. AIH Autoimmune hepatitis, cm Centimeter, CTP Child-Turcotte-Pugh, HBV Hepatitis B virus, HCC Hepatocellular carcinoma, HCV Hepatitis C virus, IQR Interquartile range, MELD Model for end-stage liver disease, N Number, NASH Non-alcoholic Steatohepatitis, SD Standard deviation